Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Current Investments (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Cash & Current Investments readings, the most recent being $155.5 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 261.71% to $155.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $155.5 million through Mar 2026, up 261.71% year-over-year, with the annual reading at $69.1 million for FY2025, 30.23% up from the prior year.
  • Cash & Current Investments hit $155.5 million in Q1 2026 for Ovid Therapeutics, up from $69.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $166.7 million in Q1 2022 and bottomed at $25.5 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $93.7 million, with a median of $88.9 million recorded in 2024.
  • The largest annual shift saw Cash & Current Investments plummeted 59.61% in 2025 before it surged 261.71% in 2026.
  • Ovid Therapeutics' Cash & Current Investments stood at $126.1 million in 2022, then decreased by 16.1% to $105.8 million in 2023, then crashed by 49.85% to $53.1 million in 2024, then surged by 30.23% to $69.1 million in 2025, then skyrocketed by 125.01% to $155.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Cash & Current Investments are $155.5 million (Q1 2026), $69.1 million (Q4 2025), and $25.5 million (Q3 2025).